
Commentary|Videos|September 16, 2024
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC
Author(s)Sanjay Popat, BSc, MBBS, FRCP, PhD
Fact checked by: Ashling Wahner , Kristi Rosa
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Advertisement
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research, discusses findings from the second interim overall survival (OS) analysis of the phase 3 MARIPOSA-2 study (NCT04988295) investigating amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with EGFR-mutated, advanced non–small cell lung cancer who have progressed on osimertinib (Tagrisso).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5



































